dining delivered

Houston in-seat ordering app gets rodeo ready, prepares for busy XFL season

A Houston startup just got a huge new client: The Houston Livestock Show and Rodeo. Photo courtesy of sEATz

A Houston startup isn't afraid to take on the 21-day Houston Livestock Show and Rodeo with its in-seat ordering technology.

Houston-based sEATz, through its partnership with Aramark and NRG Stadium, will be serving up stadium food to rodeo goers this year every single night of the show. Rather than be intimidated the size and scale of Rodeo Houston, sEATz, equipped with a recently upgraded app, is ready for the challenge.

"Twenty-one nights in a row for us is great — that just shows the flexibility and scalability of our model," says CEO and co-founder Aaron Knape.

For those headed out to the rodeo with tickets in the 100s — the lower section — sEATz will have in-seat delivery and pickup lanes. Users can download the app, plug in their seat information, order, pay, and hang tight for a delivery. SEATz will be available every night of the rodeo — from the start of the show to the concert.

The sEATz app has been freshly updated and is ready to rodeo. Photo courtesy of sEATz

Knape and co-founder and COO Marshall Law founded sEATz in 2018 after an idea Law had when he missed a key play at an Astros 2017 World Series game. Now, SEATz is active in 10 different venues and plans to roll out in 15 more this year, Knape says. The app has served fans at football and soccer games — and even delivered during the Rolling Stones concert at NRG Stadium last year.

"It's really great to be able to be a part of the rodeo as far as a provider to help enhance that experience in the stadium," Knape says. "It goes back to our model of we want to serve a venue and the fans in that venue — not necessarily a specific sport or concert."

SEATz had a busy football season, servicing the likes of The Texans, the University of Houston Cougars, and more, but turns out, football is not over. Through its partnership with Delaware North, the food and beverage provider for UH's TDECU Stadium, sEATz has added the XFL's Houston Roughnecks fans to its roster of users.

The team's first game on February 8 had over 17,000 in attendance, according to news reports. The team won 37 to 17 against the Los Angeles Wildcats. The second game for the Roughnecks is on Sunday, February 16, and the league recently announced the final championship game will be hosted in Houston.

"I think those fans came to have a really good time," Knape says of last weekend's game. "We're actually going to be quadrupling staff for Sunday's game."

SEATz, which closed is seed round last fall with $1.3 million raised, plans to raise another round early this year. The company is also actively recruiting teams and venues ahead of the baseball season, Knape says.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted